(24 days)
Not Found
No
The description focuses on mechanical aspects of the stapler (staple rows, sizes, materials) and regulatory updates. There is no mention of AI, ML, image processing, or data-driven decision making.
No.
The device is a surgical stapler used for resection, transection, and creation of anastomosis during abdominal and thoracic procedures; it does not provide therapeutic treatment.
No
Explanation: The GIA™ stapler with Tri-Staple™ technology is described as a surgical tool used for resection, transection, and creation of anastomosis, which involves cutting and joining tissue. It does not perform any diagnostic functions like detecting, measuring, or analyzing medical conditions.
No
The device description clearly details a physical stapler that places titanium staples and cuts tissue, indicating it is a hardware device, not software-only.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use/Indications for Use: The intended use is for "abdominal and thoracic surgical procedures for resection, transection and creation of anastomosis." This describes a surgical tool used directly on the patient's tissue during a procedure.
- Device Description: The description details a surgical stapler that physically cuts and staples tissue. This is a mechanical surgical instrument, not a device used to examine specimens in vitro (outside the body).
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue samples, etc.), detecting markers, or providing diagnostic information based on laboratory tests.
IVD devices are used to examine specimens obtained from the human body to provide information for the diagnosis, prevention, monitoring, treatment, or alleviation of disease. This device does not fit that description.
N/A
Intended Use / Indications for Use
The GIA™ stapler with Tri-Staple™ technology has applications in abdominal and thoracic surgical procedures for resection, transection and creation of anastomosis.
Product codes (comma separated list FDA assigned to the subject device)
GAG, GDW
Device Description
The GIA™ stapler with Tri-Staple™ technology places two triple staggered rows of titanium staples and simultaneously cuts and divides tissue between these two triple rows. The subject GIA™ stapler and cartridges with Tri-Staple™ technology are available in 60 mm and 80 mm staple line length and two staple sizes to accommodate tissue thicknesses: medium/thick and extra thick. Staplers for medium/thick tissue (purple cartridge) deploy three height-progressive rows of 3.0 mm, 3.5 mm and 4.0 mm titanium staples on either side of the tissue cut line. Staplers for extra thick tissue (black cartridge) deplov three height-progressive rows of 4.0 mm. 4.5 mm and 5.0 mm titanium staples on either side of the cut line. Each GIA™ staple™ technology may be reloaded with a GIA™ Cartridge with Tri-Staple™ Technology up to 7 times for a total of 8 firings per instrument.
The design modification is to add one contraindication per special control 21 CFR 878.4740(b)(2)(ix)(A), and revises IFUs and labels per new regulation requirements.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
abdominal, thoracic
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical performance data - Usability assessment was performed for the proposed labeling changes to demonstrate substantial equivalence to the predicate device.
Clinical performance data - No clinical study is deemed necessary since the substantial equivalence has been sufficiently demonstrated by non-clinical studies.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 878.4750 Implantable staple.
(a)
Identification. An implantable staple is a staple-like device intended to connect internal tissues to aid healing. It is not absorbable.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food & Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
April 29, 2022
Covidien Katherine Choi Senior Principal Regulatory Affairs Specialist 60 Middletown Avenue North Haven, Connecticut 06473
Re: K221006
Trade/Device Name: GIA Stapler with Tri-Staple Technology Regulation Number: 21 CFR 878.4740 Regulation Name: Surgical Stapler Regulatory Class: Class II Product Code: GAG, GDW Dated: March 30, 2022 Received: April 5, 2022
Dear Katherine Choi :
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal
1
statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Mark Trumbore Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known) K221006
Device Name GIATM Stapler with Tri-Staple™ Technology
Indications for Use (Describe)
The GIA™ stapler with Tri-Staple™ technology has applications in abdominal and thoracic surgical procedures for resection, transection and creation of anastomosis.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the
time to review instructions, search existing data sources, gather and maintain the data needed and complete
and review the collection of information. Send comments regarding this burden estimate or any other aspect
of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB number."
Form Approved: OMB No. 0910-0120
Expiration Date: 06/30/2023
See PRA Statement below.
3
510(k) Summary
Date Prepared:
Apr 22, 2022
Submitter:
Yanjun Jiao Covidien Rooms 501, 502, 601, 602, No.3 building No.2388 Chen Hang Road Min Hang District, Shanghai, 201114, China
US Contact:
Katherine Y. Choi Covidien 60 Middletown Avenue North Haven, CT 06473, USA Senior Principal Regulatory Affairs Specialist Email: katherine.y.choi@medtronic.com
Name of Device:
| Name of Device: | |
|---|---|
| Proprietary/Trade Name: | GIA™ Stapler with Tri-Staple™ Technology |
| Model Numbers: | GIA60MTS, GIA60XTS, GIA60MTC, GIA60XTC |
| GIA80MTS, GIA80XTS, GIA80MTC, GIA80XTC | |
| Classification Name: | Staple, Implantable; Stapler, Surgical |
| Regulations Number: | 21 CFR 878.4750, 21 CFR 878.4740 |
| Product Codes: | GDW, GAG |
| FDA Panel Number: | 79 |
| Device Class: | Class II |
| Review Panel: | General and Plastic Surgery |
| Common Name: | Surgical stapler with implantable staples |
| Predicate Device: | |
| Proprietary/Trade Name: | GIA™ Stapler with Tri-Staple™ Technology |
| Model Numbers: | GIA60MTS, GIA60XTS, GIA60MTC, GIA60XTC |
| GIA80MTS, GIA80XTS, GIA80MTC, GIA80XTC | |
| 510(k) Number: | K202701 (Primary Predicate Device) |
| K192720 | |
| Classification Name: | Staple, Implantable |
| Regulations Number: | 21 CFR 878.4750 |
| Product Codes: | GDW |
| FDA Panel Number: | 79 |
| Device Class: | Class II |
| Review Panel: | General and Plastic Surgery |
| Common Name: | Surgical stapler with implantable staples |
Device Description:
The GIA™ stapler with Tri-Staple™ technology places two triple staggered rows of titanium staples and simultaneously cuts and divides tissue between these two triple rows. The subject
4
GIA™ stapler and cartridges with Tri-Staple™ technology are available in 60 mm and 80 mm staple line length and two staple sizes to accommodate tissue thicknesses: medium/thick and extra thick. Staplers for medium/thick tissue (purple cartridge) deploy three height-progressive rows of 3.0 mm, 3.5 mm and 4.0 mm titanium staples on either side of the tissue cut line. Staplers for extra thick tissue (black cartridge) deplov three height-progressive rows of 4.0 mm. 4.5 mm and 5.0 mm titanium staples on either side of the cut line. Each GIA™ staple™ technology may be reloaded with a GIA™ Cartridge with Tri-Staple™ Technology up to 7 times for a total of 8 firings per instrument.
The design modification is to add one contraindication per special control 21 CFR 878.4740(b)(2)(ix)(A), and revises IFUs and labels per new regulation requirements.
Indications for Use:
The GIA™ stapler with Tri-Staple™ technology has applications in abdominal and thoracic surgical procedures for resection, transection and creation of anastomosis.
Technological and Performance Characteristics:
The subject device GIA™ stapler with Tri-Staple™ technology with a new contraindication does not change the fundamental operating principle and mechanism of action when compared to the predicate device. This Special 510(k) submission is triggered by the addition of a contraindication called for in the Labeling Guidance: a statement noting that the device "should not be used to staple tissues that are necrotic, friable, or have altered integrity, e.g., ischemic or edematous tissues." This contraindication is consistent with surgical training and practice. All GIA™ stapler with Tri-Staple™ technology are single-use manual linear staplers.
Substantial Equivalence:
The subject device with a new contraindication is substantially equivalent to the legally marketed GIA ™ stapler with Tri-Staple™ technology (K202701, K192720). The intended use, or indications of the subject device is not altered with the introduction of new contraindication.
They are same in fundamental scientific technology in that they are all sterile, single use, handheld, manual surqical instruments equipped with titanium staples intended to have applications in abdominal and thoracic surgical procedures for resection, transection and creation of anastomosis. The subject and predicate device are the same in design and are sterilized via ethylene oxide.
Summary of Studies:
Non-clinical performance data - Usability assessment was performed for the proposed labeling changes to demonstrate substantial equivalence to the predicate device.
Clinical performance data - No clinical study is deemed necessary since the substantial equivalence has been sufficiently demonstrated by non-clinical studies.
Conclusion:
Based upon the supporting data summarized above, we concluded that the subject device GIA™ Stapler with Tri-Staple™ Technology with a new contraindication is substantially equivalent to the legally-marketed device K202701, and K192720 and does not raise different questions or additional risks of safety and effectiveness than the predicate device.